Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NT 3

Drug Profile

NT 3

Alternative Names: Neurotrophic factor-3; Neurotrophin-3; NT3; Recombinant human neurotrophic factor

Latest Information Update: 22 Aug 2007

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Regeneron Pharmaceuticals; Takeda
  • Developer Amgen; Regeneron Pharmaceuticals
  • Class Analgesics; Antidementias; Antihyperglycaemics; Antiparkinsonians; Antivirals; Growth factors; Neuroprotectants
  • Mechanism of Action Neuron stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Constipation; Diabetic neuropathies; Peripheral nervous system diseases

Most Recent Events

  • 11 Jul 2003 A study has been added to the Digestive System Disorders therapeutic trials section
  • 31 Mar 2002 Suspended - Phase-II for Constipation in USA (SC)
  • 20 Nov 2001 A study has been added to the Adverse Events and Digestive System Disorders therapeutic trial sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top